Is Mounjaro Available on the NHS for Weight Loss? (October 2026)

01 · The core answer

Is Mounjaro available on the NHS for weight loss?

Yes, but not for everyone yet. Mounjaro is available on the NHS, but access is being phased in over several years. NICE recommends it for adults with a BMI of at least 35 plus at least one weight-related condition, and the NHS primary-care rollout began in June 2025 with the highest-need groups first (initially BMI 40+ with four or more qualifying conditions).⁴⁶

Our guide to Mounjaro on NHS prescription goes into the prescription route in more detail.

02 · What to do next

What this means for you

Your next step depends on where you sit against the criteria.

If you are in the earliest NHS group, speak to your GP practice first. If you are not, the NHS may reach you later, but nobody can give you a reliable date. Our overview of weight loss treatment on the NHS shows what else is offered while you wait.

Many people who meet the licensed criteria choose regulated private treatment rather than waiting.⁴ That is a personal decision. If you want to see how it works, our weight loss clinic explains the consultation and prescriber review. Your first 2.5mg pen costs £129.99 with code FIRST40 (standard price £169.99).

03 · NHS eligibility explained

Who qualifies for Mounjaro on the NHS?

The earliest NHS group is people with the highest clinical need. The rollout began in June 2025 with the highest-need groups first (initially BMI 40+ with four or more qualifying conditions).⁶

Beyond that opening stage, NICE recommends Mounjaro for adults with a BMI of at least 35 plus at least one weight-related condition.⁴ Full rollout is expected to take years.

Meeting the criteria does not give you an automatic right to an appointment on a particular date.

The same medicine is prescribed for type 2 diabetes under separate NICE guidance, so an NHS prescription for diabetes is a different pathway from weight management.⁸ If you are unsure which applies to you, ask your GP which pathway they are referring to.

04 · Ethnic-background adjustment

Do BMI thresholds change for some backgrounds?

Yes. People from South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean backgrounds are at higher risk of weight- related health problems at a lower BMI, so clinical thresholds are usually reduced by 2.5 kg/m² for these groups.⁴

If you are from one of these backgrounds, tell your GP or prescriber so your BMI is read against the adjusted threshold.

Your own BMI is simple to work out: weight in kilograms divided by height in metres squared. Your GP practice can measure it accurately, and it is worth asking them to record it so it is on file when the rollout reaches your group.

05 · How to ask your GP

How to get weight loss help on the NHS

Start with your GP practice and ask what is currently offered locally. NHS England describes weight-management injections as rolling out in stages, so what your practice can do depends on where your area has reached.⁶ Weight-loss injections also sit alongside other NHS support, which we cover in are weight loss injections available on the NHS.

Before the appointment, it helps to have these ready:

• Your recent weight, height and BMI, with the date they were measured.
• A list of weight-related conditions you have been diagnosed with, such as high blood pressure, high cholesterol, obstructive sleep apnoea, cardiovascular disease or prediabetes.
• Every medicine you take, including over-the-counter products.
• Any history of pancreatitis, gallbladder problems or thyroid cancer in you or a close relative.

Ask three direct questions. Does my practice or local service offer Mounjaro for weight management yet? Which group am I in? What is the expected wait, and what support is offered in the meantime? Write down the answers so you can compare them later.

If the answer is that your group has not opened yet, ask to be reviewed again when it does. In the meantime, a GP can talk through diet, activity and other options with you. Our page on NHS weight loss tablets covers the oral options.

06 · Licence versus NHS rules

Why the licence is wider than NHS access

The licence describes who the medicine is approved for; NHS criteria describe who the NHS funds, and they are deliberately narrower during a phased rollout. Mounjaro is licensed for weight management in adults with a BMI of 30 or above, or a BMI between 27 and 30 with at least one weight-related condition such as high blood pressure, high cholesterol, obstructive sleep apnoea, cardiovascular disease, prediabetes or type 2 diabetes.¹

It must be used alongside a reduced-calorie diet and increased physical activity. A prescriber will assess your BMI, medical history and current medicines before deciding whether it is suitable for you.¹¹

So you can be clinically suitable under the licence without yet qualifying for an NHS prescription. That gap is not a judgement that you do not need treatment.

Debate about how the NHS has set its guidance is covered in our piece on NHS weight loss jabs guidance.

07 · What Mounjaro is and does

What Mounjaro is, and what GLP-1 medicines are used for

Mounjaro is the brand name for tirzepatide, a once-weekly injectable prescription medicine made by Eli Lilly. In the UK it is licensed for weight management in adults and for type 2 diabetes. It comes as a pre-filled multi-dose pen (KwikPen) in six strengths: 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg and 15mg.¹

Tirzepatide is the first treatment of its kind to activate two natural gut-hormone receptors at once: GIP and GLP-1. Together these help regulate appetite, slow how quickly the stomach empties, and improve the way the body responds to insulin. In practice, most people feel fuller sooner and less hungry between meals, which supports a reduced-calorie diet.¹

This dual action is what distinguishes Mounjaro from single-action GLP-1 medicines such as semaglutide (Wegovy/Ozempic).¹

08 · What results to expect

What trial results show, and what they do not

The main trial for Mounjaro in weight management is SURMOUNT-1. In the SURMOUNT-1 trial of 2,539 adults, people taking tirzepatide alongside diet and exercise lost on average 15% of their body weight on 5mg, 19.5% on 10mg and 20.9% on 15mg over 72 weeks, compared with 3.1% with lifestyle changes alone.²

These are trial averages — individual results vary, and treatment works alongside a reduced-calorie diet and increased physical activity, not instead of them.² Trial averages do not predict your own result, and the same applies whether Mounjaro is prescribed on the NHS or privately.

The medicine supports a reduced-calorie diet; it does not replace one.

09 · Safety and who should not take it

Who should not take Mounjaro

Mounjaro is not suitable for everyone. You should not take it if you are allergic to tirzepatide or any of its ingredients, and it should not be used during pregnancy or while trying to conceive.¹³ Mounjaro must not be used during pregnancy, and it should be stopped at least one month before trying to conceive. If you become pregnant during treatment, stop the medicine and tell your prescriber promptly.

Your prescriber will take extra care, or may recommend against treatment, if you have a history of pancreatitis, severe gut or digestive disease, diabetic retinopathy, or gallbladder problems. Always share your full medical history and medicine list during consultation.¹³

On thyroid safety: in rodent studies tirzepatide caused thyroid C-cell tumours; it is not known whether this applies to humans, and no increase has been shown in human trials. As a precaution, tell your prescriber if you or a close relative have had medullary thyroid cancer or the inherited condition MEN 2 — they will weigh this in your assessment. Routine thyroid monitoring is not required for most people.¹

These checks apply on the NHS and privately. Serious side effects are uncommon but need urgent attention. Seek immediate medical help for severe, persistent stomach pain that may spread to your back, with or without vomiting (possible pancreatitis); pain in the upper right abdomen, fever or yellowing of skin or eyes (possible gallbladder problems); or signs of a severe allergic reaction such as swelling of the face or throat and difficulty breathing. If you notice any other new or lasting symptom, tell your prescriber and report it through the Yellow Card scheme.

10 · The private route

If you do not yet qualify on the NHS

A regulated private prescription is the other route, and it follows the licence rather than the NHS rollout stage. Mounjaro is a prescription-only medicine, supplied only after an online consultation reviewed by a GPhC-registered prescriber. It is used alongside a reduced-calorie diet and increased physical activity. Individual results vary.

Payment is taken when you place the order; if the prescriber decides the treatment is not suitable, the order is refunded automatically in full. Supply is through official LillyDirect, and all six doses are in stock. Orders placed by 3pm are dispatched the same day, with free next-day tracked delivery in temperature-controlled packaging.

Cost is a real consideration, so here is the plain picture. A Mounjaro pen at the 2.5mg starting dose has a standard price of £169.99 per month. New customers save £40 on a first order with code FIRST40, and every later order gets an automatic £25 off (code DOSE25). Across the UK pharmacies we track, 2.5mg starting pens range from £143.96 to £179.99 per month (checked 11 October 2026).

Our guide to weight loss injection access compares NHS and private routes side by side.

If you ever need to stop or switch treatment, tirzepatide has a half-life of about five days, so after a final dose it takes roughly four to five weeks to clear the system. There is no way to speed this up, and nothing needs doing while it clears.¹

11 · Devolved nations and storage

Scotland, Wales and Northern Ireland

NHS services are run separately in each UK nation, so availability and timing can differ. Our guide to Mounjaro on NHS Scotland covers the Scottish position. For Wales and Northern Ireland, ask your GP or local health board what is currently offered.

If you are prescribed Mounjaro by any route, store unopened pens in the fridge at 2–8°C until first use; they keep until the printed expiry date. Once in use, a KwikPen can be kept out of the fridge at a temperature not above 30°C for up to 30 days, and must then be thrown away. Follow the patient information leaflet for the rest.¹³

Mounjaro (tirzepatide) is a prescription-only medicine. This page is information, not a substitute for medical advice.